Monopar Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview

Monopar Therapeutics

06/08/2024 19:35

* Monopar Therapeutics Inc  MNPR.OQ   MNPR.O  is expected
to show
no change in quarterly revenue when it reports  results on
August 8 (estimated) for the period ending June 30 2024
    * 
    * ​LSEG's mean analyst estimate for Monopar Therapeutics Inc
is
for a loss of 9 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 17.2%
in the last three months. ​
    * Wall Street's median 12-month price target for Monopar
Therapeutics Inc is $2.00​, above​ its last closing price
of $0.61. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.12       -0.12      -0.10     Beat    16.7
 Dec. 31 2024              -0.15      -0.12     Beat    22.6
 Jan. 1 0001   -0.15       -0.17      -0.14     Beat    17.6​
 Jan. 1 0001   -0.18       -0.18      -0.16     Beat    13
 ​​Jan.        -0.22       -0.22      -0.19     Beat    14.4
 1 0001                                                 
 Dec. 31 2022  -0.20       -0.20      -0.23     Missed  -12.2​
 Sep. 30 2022  -0.21                  -0.19             12.6
 Jan. 1 0001   -0.20       -0.21      -0.22     Missed  -6.4
 This summary was machine generated August 6 at 18:34 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)